Kumar Prashant, Tiwari Kaousthubh, Pendyala Siva Kumar, Jaiswal Ratnesh Kumar, Chacko Neelathil Lisa, Srivastava Ekta, Tiwari Rahul V C
Department of Cardiology, Rajendra Institute of Medical Science, Ranchi, Jharkhand, India.
General Physician, Rollz India Waste Management Pvt. Ltd, Ghaziabad, Uttar Pradesh, India.
J Pharm Bioallied Sci. 2021 Nov;13(Suppl 2):S1333-S1337. doi: 10.4103/jpbs.jpbs_143_21. Epub 2021 Nov 10.
The viral infection COVID-19 is highly infectious and has claimed many lives till date and is still continuing to consume lives. In the COVID-19, along with pulmonary symptoms, cardiovascular (CV) events were also recorded that have known to significantly contribute to the mortality. In our study, we designed and validated a new risk score that can predict CV events, and also evaluated the effect of these complications on the prognosis in COVID-19 patients.
A retrospective, multicenter, observational study was done among 1000 laboratory-confirmed COVID-19 patients between June 2020 and December 2020. All the data of the clinical and laboratory parameters were collected. Patients were randomly divided into two groups for testing and validating the hypothesis. The identification of the independent risk factors was done by the logistic regression analysis method.
Of all the types of the clinical and laboratory parameters, ten "independent risk factors" were identified associated with CV events in Group A: male gender, older age, chronic heart disease, cough, lymphocyte count <1.1 × 10/L at admission, blood urea nitrogen >7 mmol/L at admission, estimated glomerular filtration rate <90 ml/min/1.73 m at admission, activated partial thromboplastin time >37 S, D-dimer, and procalcitonin >0.5 mg/L. In our study, we found that CV events were significantly related with inferior prognosis ( < 0.001).
A new risk scoring system was designed in our study, which may be used as a predictive tool for CV complications among the patients with COVID-19 infection.
新冠病毒感染（COVID-19）具有高度传染性，迄今为止已夺去许多人的生命，并且仍在继续吞噬生命。在COVID-19中，除了肺部症状外，还记录到心血管（CV）事件，已知这些事件会显著增加死亡率。在我们的研究中，我们设计并验证了一种新的风险评分，该评分可以预测CV事件，并评估这些并发症对COVID-19患者预后的影响。
对2020年6月至2020年12月期间1000例实验室确诊的COVID-19患者进行了一项回顾性、多中心、观察性研究。收集了所有临床和实验室参数的数据。患者被随机分为两组以检验和验证假设。通过逻辑回归分析方法确定独立危险因素。
在所有类型的临床和实验室参数中，在A组中确定了与CV事件相关的10个“独立危险因素”：男性、年龄较大、慢性心脏病、咳嗽、入院时淋巴细胞计数<1.1×10⁹/L、入院时血尿素氮>7 mmol/L、入院时估计肾小球滤过率<90 ml/min/1.73 m²、活化部分凝血活酶时间>37 S、D-二聚体以及降钙素原>0.5 mg/L。在我们的研究中，我们发现CV事件与较差的预后显著相关（P<0.001）。
我们的研究设计了一种新的风险评分系统，可作为COVID-19感染患者CV并发症的预测工具。
